Cash runway anticipated to be extended from Q2 2025 to Q4 2025Data from multiple Phase 1 and 2 clinical trials expected in 2024 OXFORD, United Kingdom, Jan. 05, 2024 Barinthus Biotherapeutics.
Barinthus Bio Provides a Financial Update and Announces Anticipated 2024 Corporate Milestones tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.
Fort Lee, NJ, Jan. 03, 2024 Nuvectis Pharma, Inc. , a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious.
CEPI to invest funding of up to $34.8 million to Barinthus Bio in addition to funds previously committed to the University of Oxford to develop and stockpile a ready reserve of emergency MERS vaccine.